Effect of the principle of activating blood circulation to break stasis on GMP-140 and D2 dimer in patients with acute cerebral infarction.
OBJECTIVE
To explore the clinical efficacy of the principle of activating blood circulation to break stasis (ABCBS) and its influence on platelet membranous protein particle (GMP-140) and D(2) dimer (D-dimer) before and after treatment.


METHODS
Eighty-eight patients with blood stasis syndrome (BSS) of acute cerebral infarction (ACI) were randomly divided into two groups, both of which were treated with conventional treatment, i.e. with western medicine (WM), with Salvia injection added through intravenously dripping. One of the two groups was used as the control and the other group as the treated group who had ABCBS herbs orally taken in addition. The duration of treatment course for both groups was 3 weeks.


RESULTS
There were changes in both groups over clinical symptoms, nerve function deficit scoring and GMP-140, D-dimer, but the treated group showed significantly better than that of the control group, (P < 0.05).


CONCLUSIONS
ABCBS principle could serve as an important auxiliary treating method for BSS of ACI, as it can effectively alter the blood of ACI patients which was viscous, condense, coagulant and aggregating.
Wang
Ning
N
Neurology Department, Hospital Affiliated to Nanjing University of TCM, China.
D000208:Acute Disease; D000368:Aged; D001241:Aspirin / Q000627:therapeutic use; D001775:Blood Circulation / Q000187:drug effects; D001792:Blood Platelets / Q000378:metabolism; D002544:Cerebral Infarction / Q000097:blood / Q000503:physiopathology* / Q000628:therapy*; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D006801:Humans; D008297:Male; D008516:Medicine, Chinese Traditional; D008875:Middle Aged; D009420:Nervous System / Q000503:physiopathology; D009553:Nimodipine / Q000627:therapeutic use; D019007:P-Selectin / Q000097:blood; D008517:Phytotherapy; D028321:Plant Preparations / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D027544:Salvia; D014665:Vasodilator Agents / Q000627:therapeutic use
D005338:Fibrin Fibrinogen Degradation Products; D019007:P-Selectin; D028321:Plant Preparations; D010975:Platelet Aggregation Inhibitors; D014665:Vasodilator Agents; C036309:fibrin fragment D; D009553:Nimodipine; D001241:Aspirin